Tumor-derived TGF-β and prostaglandin E2 attenuate anti-tumor immune responses in head and neck squamous cell carcinoma treated with EGFR inhibitor

BACKGROUND: EGFR-targeted therapy is an attractive option for head and neck squamous cell carcinoma patients. We have recently reported the use of EGFR inhibitors as an adjunct treatment to enhance HLA-DR expression in tumor cells to improve cancer immunotherapy. Nevertheless, we observed that EGFR...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Kumai, Takumi, Oikawa, Kensuke, Aoki, Naoko, Kimura, Shoji, Harabuchi, Yasuaki, Celis, Esteban, Kobayashi, Hiroya
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: BioMed Central 2014
Aiheet:
Research
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4177691/
https://ncbi.nlm.nih.gov/pubmed/25240937
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12967-014-0265-3
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia